O46.011 Antepartum hemorrhage with afibrinogenemia, first trimester

Name of the Condition

• Antepartum Hemorrhage with Afibrinogenemia, First Trimester

Summary

Antepartum hemorrhage refers to bleeding from the genital tract during pregnancy. In this case, the bleeding occurs in the first trimester and is associated with afibrinogenemia, a rare condition where the blood lacks fibrinogen, a key protein for clotting. This deficiency can exacerbate bleeding and complicate management.

Causes

Afibrinogenemia may be inherited (congenital) or acquired. Congenital cases result from genetic mutations affecting fibrinogen production. Acquired afibrinogenemia can arise from severe liver disease, disseminated intravascular coagulation (DIC), or massive blood loss that depletes fibrinogen stores. In pregnancy, it may be triggered by complications like placental abruption or miscarriage.

Risk Factors

• Preexisting congenital afibrinogenemia or family history of bleeding disorders
• Severe liver dysfunction
• Previous episodes of DIC or massive hemorrhage
• Conditions associated with increased fibrinogen consumption (e.g., severe infection, trauma)
• Multiple pregnancies or advanced maternal age

Symptoms

• Vaginal bleeding (ranging from spotting to heavy flow)
• Excessive bruising or prolonged bleeding from minor injuries
• Abdominal pain or cramping
• Fatigue or weakness (due to blood loss)
• Signs of coagulation failure, such as uncontrolled bleeding or petechiae

Diagnosis

Diagnosis involves assessing the bleeding pattern and evaluating coagulation status. Laboratory tests confirm afibrinogenemia by measuring low or absent fibrinogen levels. Imaging (e.g., ultrasound) may assess pregnancy viability and identify sources of bleeding. Clinical correlation with symptoms and history is essential.

Treatment Options

Management focuses on controlling bleeding and replacing fibrinogen. Fresh frozen plasma or cryoprecipitate may be administered to restore clotting. In severe cases, blood transfusions or hemostatic agents may be used. Underlying causes (e.g., placental issues) are addressed, and close monitoring of maternal and fetal status is critical.

Prognosis and Follow-Up

Prognosis depends on the severity of bleeding and timely intervention. With appropriate treatment, outcomes can be favorable, but delays may increase risks of maternal or fetal complications. Follow-up includes monitoring coagulation levels, assessing for recurrence, and managing any underlying conditions.

Complications

• Severe maternal hemorrhage requiring transfusion
• Fetal distress or loss
• Prolonged recovery from blood loss
• Risk of recurrence in future pregnancies
• Potential for other coagulation disorders if underlying causes persist

Lifestyle & Prevention

• Avoid activities with high injury risk during pregnancy.
• Maintain regular prenatal care to monitor coagulation status.
• Inform healthcare providers of any bleeding history or family disorders.
• Follow prescribed treatments for underlying conditions (e.g., liver disease).

When to Seek Professional Help

Seek immediate care for heavy vaginal bleeding, severe abdominal pain, dizziness, or signs of shock (e.g., rapid heart rate, low blood pressure). Prompt evaluation is critical to manage bleeding and prevent complications.

Tips for Medical Coders

Document the trimester (first trimester) and confirm the presence of afibrinogenemia. Ensure clinical notes support the diagnosis, including lab results or specialist confirmation. Code O46.011 is specific to first-trimester antepartum hemorrhage with afibrinogenemia; no additional codes are needed unless other conditions are documented.